Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Exp Biol ; 221(Pt 19)2018 10 01.
Article in English | MEDLINE | ID: mdl-30104306

ABSTRACT

For insects, chilling injuries that occur in the absence of freezing are often related to a systemic loss of ion and water balance that leads to extracellular hyperkalemia, cell depolarization and the triggering of apoptotic signalling cascades. The ability of insect ionoregulatory organs (e.g. the Malpighian tubules) to maintain ion balance in the cold has been linked to improved chill tolerance, and many neuroendocrine factors are known to influence ion transport rates of these organs. Injection of micromolar doses of CAPA (an insect neuropeptide) have been previously demonstrated to improve Drosophila cold tolerance, but the mechanisms through which it impacts chill tolerance are unclear, and low doses of CAPA have been previously demonstrated to cause anti-diuresis in insects, including dipterans. Here, we provide evidence that low (femtomolar) and high (micromolar) doses of CAPA impair and improve chill tolerance, respectively, via two different effects on Malpighian tubule ion and water transport. While low doses of CAPA are anti-diuretic, reduce tubule K+ clearance rates and reduce chill tolerance, high doses facilitate K+ clearance from the haemolymph and increase chill tolerance. By quantifying CAPA peptide levels in the central nervous system, we estimated the maximum achievable hormonal titres of CAPA and found further evidence that CAPA may function as an anti-diuretic hormone in Drosophila melanogaster We provide the first evidence of a neuropeptide that can negatively affect cold tolerance in an insect and further evidence of CAPA functioning as an anti-diuretic peptide in this ubiquitous insect model.


Subject(s)
Antidiuretic Agents/metabolism , Body Temperature Regulation/physiology , Drosophila Proteins/metabolism , Drosophila melanogaster/physiology , Malpighian Tubules/metabolism , Neuropeptides/metabolism , Animals , Antidiuretic Agents/administration & dosage , Body Temperature Regulation/drug effects , Cold Temperature , Drosophila Proteins/administration & dosage , Drosophila melanogaster/drug effects , Ions/metabolism , Neuropeptides/administration & dosage , Water/metabolism
2.
Int J Pharm ; 440(2): 229-37, 2013 Jan 20.
Article in English | MEDLINE | ID: mdl-22743007

ABSTRACT

The purpose of this study was to investigate the potential of intranasal immunization with non-ionic surfactant vesicles (NISV) containing either the secretory recombinant form of glycoprotein B (gBs) of herpes simplex virus type 1 or a related polylysine reach peptides (DTK) for induction of protective immunity against genital herpes infection in mice. NISV were prepared by lipid film hydration method. The mean diameter of vesicles was around 390 nm for DTK-containing NISV (DTK-NISV) and 320 nm for gB1s-containing NISV (gB1s-NISV). The encapsulation efficiency of the molecules was comprised between 57% and 70%. After 7-14 day NISV maintained stable dimensions and a drug encapsulation higher than 48%. We showed that intranasal immunization with gB1s-NISV induces gB-specific IgG antibody and lymphoproliferative responses, whereas vaccination with DTK-NISV was not able to generate a gB-specific immune response. Our results indicate that vaccination of BALB/c mice with gB1s-NISV induced Th1 responses, as characterized by increased titre of IG2a in plasma and IFN-production in CD4+ splenic cells. Intranasal immunization with gB1s-NISV could elicit 90% (almost complete) protection against a heterologous lethal vaginal challenge with herpes simplex virus type 2. These data may have implications for the development of a mucosal vaccine against genital herpes.


Subject(s)
Herpes Genitalis/prevention & control , Herpes Simplex Virus Vaccines/therapeutic use , Immunization/methods , Liposomes/therapeutic use , Surface-Active Agents/therapeutic use , Administration, Intranasal , Animals , Antibodies, Viral/blood , Chlorocebus aethiops , Cytokines/metabolism , Drosophila Proteins/administration & dosage , Drosophila Proteins/immunology , Herpes Genitalis/blood , Herpes Genitalis/immunology , Herpes Simplex Virus Vaccines/administration & dosage , Herpes Simplex Virus Vaccines/immunology , Herpesvirus 2, Human/immunology , Humans , Immunoglobulin G/immunology , Immunoglobulin G/metabolism , Liposomes/administration & dosage , Liposomes/chemical synthesis , Lymphocyte Activation/immunology , Mice , Mice, Inbred BALB C , Particle Size , Protein Precursors/administration & dosage , Protein Precursors/immunology , Spleen/immunology , Spleen/metabolism , Surface-Active Agents/administration & dosage , Surface-Active Agents/chemistry , Tachykinins/administration & dosage , Tachykinins/immunology , Vero Cells , Viral Envelope Proteins/administration & dosage , Viral Envelope Proteins/immunology , Viral Envelope Proteins/therapeutic use
3.
J Neurosci ; 29(15): 4964-71, 2009 Apr 15.
Article in English | MEDLINE | ID: mdl-19369565

ABSTRACT

In amyloid precursor protein (APP) models of amyloid deposition, the amount of amyloid deposits increase with mouse age. At a first approximation, the extent of amyloid accumulation may either reflect small excesses of production over clearance that accumulate over time or, alternatively, indicate a steady-state equilibrium at that age, reflecting the instantaneous excess of production over clearance, which increases as the organism ages. To discriminate between these options, we reversibly suppressed amyloid deposition in Tg2576 mice with the anti-Abeta antibody 2H6, starting at 8 months, just before the first histological deposits can be discerned. Six months later, we stopped the suppression and monitored the progression of amyloid accumulation in control APP mice and suppressed APP mice over the next 3 months. The accumulation hypothesis would predict that the rate of amyloid from 14 to 17 months would be similar in the suppressed and control mice, while the equilibrium hypothesis would predict that the increase would be faster in the suppressed group, possibly catching up completely with the control mice. The results strongly support the accumulation hypothesis, with no evidence of the suppressed mice catching up with the control mice as predicted by equilibrium models. If anything, there was a slower rate of increase in the suppressed APP mice than the control mice, suggesting that a slow seeding mechanism likely precedes a rapid fibrillogenesis in determining the extent of amyloid deposition.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Protein Precursor/metabolism , Alzheimer Disease/prevention & control , Amyloid beta-Protein Precursor/antagonists & inhibitors , Amyloid beta-Protein Precursor/immunology , Animals , Antibodies/administration & dosage , Brain/metabolism , Brain/pathology , Drosophila Proteins/administration & dosage , Mice , Mice, Transgenic , Plaque, Amyloid/metabolism , Plaque, Amyloid/pathology , Time Factors
4.
Biochem Biophys Res Commun ; 350(4): 994-9, 2006 Dec 01.
Article in English | MEDLINE | ID: mdl-17046713

ABSTRACT

The peptidoglycan recognition protein (PGRP) family is conserved from insects to mammals and is involved in immune regulation and bacterial clearance. They form at least three functional classes; receptors required for immune gene expression; amidases that degrade peptidoglycan and scavenge the tissues from immune-stimulating peptidoglycan; and as proteins with antibacterial activity. We here report that PGRP-SB1 is an N-acetylmuramoyl l-alanine amidase, which (in contrast to the previously described PGRP-amidases) shows antibacterial activity. PGRP-SB1 is highly active against peptidoglycans that have a diaminopimelic acid (DAP) residue in the cross-linking peptide, but lack activity to most lysine-containing peptidoglycans. The antibacterial activity is pronounced against Bacillus megaterium with an LD(50) of 1.5microg ml(-1). The bactericidal effect of PGRP-SB1 is dependent on its enzymatic activity, as the zinc co-factor is essential. The bactericidal mode of action is thus different from non-enzymatic vertebrate PGRPs that have been reported to be antibacterial.


Subject(s)
Bacillus megaterium/cytology , Bacillus megaterium/drug effects , Carrier Proteins/administration & dosage , Drosophila Proteins/administration & dosage , Anti-Bacterial Agents/administration & dosage , Cell Survival/drug effects , Dose-Response Relationship, Drug
5.
Pain ; 113(3): 271-276, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15661433

ABSTRACT

Spinal noradrenaline (NA) released in response to noxious stimuli may play an important role in suppression of nociceptive transmission. Here, we investigated the efficacy of a competitive NA transporter inhibitor (reboxetine) and a noncompetitive NA transporter inhibitor peptide, Xen2174, isolated from the Pacific cone snail, to treat tactile hypersensitivity following paw incisional surgery. Male Sprague-Dawley rats were anesthetized, an incision of the plantar aspect of the hind paw was performed, and withdrawal threshold to von Frey filaments near the surgical site determined. Reboxetine (0.5-5 microg) and Xen2174 (0.3-100 microg) increased withdrawal threshold when injected 24h after paw incision, with a peak effect at 15-60 min, for Xen2174, an ED50 value of 0.64 microg. Administration of Xen2174 (3-30 microg) 15 min before incision also reduced hypersensitivity in a dose-dependent manner. Withdrawal threshold after the single 30 microg dose was greater than vehicle control even at 2, 3, and 5 days after incision. Doses

Subject(s)
DNA-Binding Proteins/administration & dosage , Drosophila Proteins/administration & dosage , Hyperalgesia/prevention & control , Morpholines/administration & dosage , Pain, Postoperative/drug therapy , Spinal Cord/drug effects , Transcription Factors/administration & dosage , Adrenergic Uptake Inhibitors/administration & dosage , Adrenergic alpha-Antagonists/pharmacology , Analysis of Variance , Animals , Atropine/pharmacology , Behavior, Animal/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Interactions , Hyperalgesia/etiology , Idazoxan/pharmacology , Male , Muscarinic Antagonists/pharmacology , Pain Threshold/drug effects , Pain, Postoperative/complications , Peptides/therapeutic use , Rats , Rats, Sprague-Dawley , Reboxetine , Snail Family Transcription Factors , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL